title: Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa.
abstract: Hidradenitis suppurativa/acne inversa (HS) is a chronic inflammatory skin disease characterized by painful, recurrent nodules and abscesses that rupture and lead to sinus tracts and scarring. To date, an evidence-based therapeutic approach has not been the standard of care and this is likely due to the lack of evidence based treatment guidelines. The purpose of this study was to promote a holistic evidence-based approach which implemented Level of Evidence and Strength of Recommendation for the treatment of HS. Based upon the European Dermatology Forumguidelines for the management of HS, evidence-based approach was explored for the treatment of HS. The diagnosis of HS should be made by a dermatologist or other healthcare professional with expert knowledge in HS. All patients should be offered adjuvant therapy as needed (pain management, weight loss, tobacco cessation, treatment of super infections, and application of appropriate dressings). The treating physician should be familiar with disease severity scores, especially Hurley staging, physician global assessment and others. The routine use of patient'reported outcomesincluding DLQI, itch and pain assessment (Visual Analogue Scale) is strongly recommended. The need for surgical intervention should be assessed in all patients depending upon type and extent of scarring, and an evidence-based surgical approach should be implemented. Evidence-based medical treatment of mild disease consists of topical Clindamycin 1 % solution/gel b.i.d. for 12 weeks or Tetracycline 500 p.o. b.i.d. for 4 months (LOE IIb, SOR B), for more widespread disease. If patient fails to exhibit response to treatment or for a PGA of moderate-to-severe disease, Clindamycin 300 p.o. b.i.d. with Rifampicin 600 p.o. o.d. for 10 weeks (LOE III, SOR C) should be considered. If patient is not improved, then Adalimumab 160 mg at week 0, 80 mg at week 2; then 40 mg subcutaneously weekly should be administered (LOE Ib, SOR A). If improvement occurs then therapy should be maintained as long as HS lesions are present. If the patient fails to exhibit response, then consideration of second or third line therapy is required. A growing body of evidence is being published to guide the treatment of HS. HS therapy should be based upon the evaluation of the inflammatory components as well as the scarring and should be directed by evidence-based guidelines. Treatment should include surgery as well as medical treatment. Future studies should include benefit risk ratio analysis and long term assessment of efficacy and safety, in order to facilitate long term evidence based treatment and rational pharmacotherapy.
authors.affiliation: European Hidradenitis Suppurativa Foundation e.V, Dessau, Germany. WGulliver@newlabresearch.com.|Faculty of Medicine, Memorial University of Newfoundland, St. John's, Newfound land & Labrador, Canada. WGulliver@newlabresearch.com.
authors.forename: Wayne
authors.initials: W
authors.lastname: Gulliver
authors.affiliation: European Hidradenitis Suppurativa Foundation e.V, Dessau, Germany.|Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Dessau, Germany.
authors.forename: Christos C
authors.initials: CC
authors.lastname: Zouboulis
authors.affiliation: European Hidradenitis Suppurativa Foundation e.V, Dessau, Germany.|Department of Dermatology, Erasmus MC, Rotterdam, The Netherlands.
authors.forename: Errol
authors.initials: E
authors.lastname: Prens
authors.affiliation: European Hidradenitis Suppurativa Foundation e.V, Dessau, Germany.|Department of Dermatology, Roskilde Hospital, Health Sciences Faculty, University of Copenhagen, Copenhagen, Denmark.
authors.forename: Gregor B E
authors.initials: GB
authors.lastname: Jemec
authors.affiliation: European Hidradenitis Suppurativa Foundation e.V, Dessau, Germany.|Department of Dermatology, Faculty of Health Sciences, University Hospital of North Norway, Harstad, Troms, Norway.
authors.forename: Thrasivoulos
authors.initials: T
authors.lastname: Tzellos
mesh_terms: D005060:Europe; D055317:Evidence-Based Practice; D017497:Hidradenitis Suppurativa / Q000175:diagnosis / Q000188:drug therapy / Q000601:surgery; D006801:Humans; D017410:Practice Guidelines as Topic
keywords: Evidence-based dermatology; Guidelines; Hidradenitis suppurativa; Medical therapy; Surgical therapy
references.citation: Ann Intern Med. 2012 Dec 18;157(12):846-55
references.pmid: 23247938
references.citation: Dermatol Surg. 2000 Jul;26(7):638-43
references.pmid: 10886270
references.citation: J Eur Acad Dermatol Venereol. 2015 Aug;29(8):1590-7
references.pmid: 25589154
references.citation: Dis Colon Rectum. 1990 Sep;33(9):731-4
references.pmid: 2390907
references.citation: BMJ. 2008 Apr 26;336(7650):924-6
references.pmid: 18436948
references.citation: Surgeon. 2005 Feb;3(1):23-6
references.pmid: 15789789
references.citation: Scand J Plast Reconstr Surg Hand Surg. 2001 Sep;35(3):305-9
references.pmid: 11680401
references.citation: Br J Dermatol. 1988 Sep;119(3):345-50
references.pmid: 3179207
references.citation: Dermatol Surg. 2015 Feb;41(2):255-60
references.pmid: 25654196
references.citation: Dermatoendocrinol. 2010 Jan;2(1):9-16
references.pmid: 21547142
references.citation: J Am Acad Dermatol. 1998 Dec;39(6):971-4
references.pmid: 9843011
references.citation: J Eur Acad Dermatol Venereol. 2015 Feb;29(2):371-6
references.pmid: 24909646
references.citation: Dermatology. 2009;219(2):148-54
references.pmid: 19590173
references.citation: J Surg Res. 2013 Sep;184(1):658-64
references.pmid: 23768766
references.citation: J Am Acad Dermatol. 2010 Sep;63(3):475-80
references.pmid: 20708472
references.citation: J Am Acad Dermatol. 2010 Apr;62(4):637-45
references.pmid: 20227579
references.citation: Paediatr Drugs. 2014 Dec;16(6):483-9
references.pmid: 25234961
references.citation: J Am Acad Dermatol. 2008 Oct;59(4):596-601
references.pmid: 18674845
references.citation: J Am Acad Dermatol. 2013 Mar;68(3):412-9
references.pmid: 22921795
references.citation: J Am Acad Dermatol. 1996 Aug;35(2 Pt 1):191-4
references.pmid: 8708018
references.citation: J Eur Acad Dermatol Venereol. 2012 Jul;26(7):898-902
references.pmid: 21812838
references.citation: Arch Dermatol. 2012 Apr;148(4):439-46
references.pmid: 22184715
references.citation: Int J Colorectal Dis. 1998;13(4):164-8
references.pmid: 9810520
references.citation: Plast Reconstr Surg. 2011 Aug;128(2):459-65
references.pmid: 21788837
references.citation: Dermatol Surg. 2009 Aug;35(8):1188-98
references.pmid: 19438670
references.citation: Dermatol Surg. 2010 Feb;36(2):208-13
references.pmid: 20039918
references.citation: Dermatol Surg. 2008 Feb;34(2):224-7
references.pmid: 18093197
references.citation: Int J Dermatol. 1983 Jun;22(5):325-8
references.pmid: 6347922
references.citation: Dermatol Surg. 2010 Dec;36(12):1998-2004
references.pmid: 21040127
references.citation: J Invest Dermatol. 2013 Jan;133(1):97-103
references.pmid: 22931916
references.citation: J Clin Epidemiol. 2013 Jul;66(7):726-35
references.pmid: 23570745
references.citation: J Am Acad Dermatol. 2002 Aug;47(2):280-5
references.pmid: 12140476
references.citation: J Eur Acad Dermatol Venereol. 2013 Aug;27(8):1015-21
references.pmid: 22817107
references.citation: Clin Exp Dermatol. 2001 Sep;26(6):501-3
references.pmid: 11678875
references.citation: J Am Acad Dermatol. 2012 Sep;67(3):422-8, 428.e1
references.pmid: 22182915
references.citation: Exp Dermatol. 2008 May;17(5):455-6; discussion 457-72
references.pmid: 18400064
references.citation: J Am Acad Dermatol. 2010 Feb;62(2):205-17
references.pmid: 20115947
references.citation: Plast Reconstr Surg. 2014 Mar;133(3):370e-377e
references.pmid: 24572882
references.citation: JAMA Dermatol. 2013 Jun;149(6):732-5
references.pmid: 23552442
references.citation: Br J Dermatol. 2001 Apr;144(4):809-13
references.pmid: 11298541
references.citation: BMC Dermatol. 2012 Jun 26;12:9
references.pmid: 22734714
references.citation: J Eur Acad Dermatol Venereol. 2015 Apr;29(4):619-44
references.pmid: 25640693
references.citation: J Am Acad Dermatol. 2015 Mar;72(3):485-8
references.pmid: 25582541
references.citation: Br J Dermatol. 2014 Dec;171(6):1434-42
references.pmid: 25040429